Ayelet Dilion Mashiah is the CEO of Remedy Cell.

She has more than 20 years executive leadership in the life science Industry.

She has been the CEO of Newstem Ltd.: a pre-clinical bio-platform company for the developments of anti-cancer drugs base on Synthetic Lethality, CEO of BioMAS Ltd. ; a Phase II clinical company, Focusing on Tellurium-based compounds for pharmaceuticals. Products sold to Cosmo Pharmaceuticals (SWX: COPN) and Feramda Ltd., CEO of Do-Coop Technologies, an innovative nano-biotechnology startup and Director for TEVA’s Corporate Economic Department (NYSE:TEVA)